Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
Full name:
Authorised dose form:
Legal status of supply:
Domain:
Resource status:
Product classification:
Document Details
Generated Narrative: Bundle TEST PURPOSES ONLY - caprelsa
Language: en
Profile: Bundle - ePI
Final Document at 2022-02-16 13:28:17+0000 by Organization ACME industry for Bundle: identifier = http://ema.europa.eu/identifier#None; type = document; timestamp = 2023-06-27 10:09:22+0000
Document Subject
Generated Narrative: MedicinalProductDefinition mpf3d8b9999dbf0bb7ed96cabee591db10
identifier: http://ema.europa.eu/identifier
/EU/1/11/749/001
type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Caprelsa 100 mg film-coated tablets
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en
Document Content
Generated Narrative: Composition composition-en-f3d8b9999dbf0bb7ed96cabee591db10
Language: en
Profile: Composition (ePI)
identifier: http://ema.europa.eu/identifier
/EU/1/11/749/001
status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - caprelsa
Mode | Time |
Official | 2022-02-16 13:28:17+0000 |
What is in this leaflet:
Caprelsa is a treatment for adults and children aged 5 years and above with:
Type of medullary thyroid cancer that is called Rearranged during Transfection (RET) mutant and which cannot be removed by surgery or has spread to other parts of the body.
Caprelsa works by slowing down the growth of new blood vessels in tumours (cancers). This cuts off the supply of food and oxygen to the tumour. Caprelsa may also act directly on cancer cells to kill them or slow down their growth.
Do not take Caprelsa:
Do not take Caprelsa if any of the above applies to you. If you are not sure, talk to your doctor.
Warnings and precautions
Talk to your doctor or pharmacist before taking Caprelsa:
Severe Cutaneous Adverse Reactions (SCARs), including Stevens-Johnson syndrome (SJS) / toxic epidermal necrolysis (TEN), have been reported in association with vandetanib treatment. Stop using Caprelsa and seek medical attention immediately if you notice any of the symptoms related to these serious skin reactions described in section 4. Determination of RET status of your cancer will be needed, before initiating Caprelsa treatment.
Monitoring of your blood and your heart: Your doctor or nurse should perform tests to check the levels of your blood potassium, calcium, magnesium, and thyroid-stimulating hormone (TSH) as well as the electrical activity of your heart with a test called an electrocardiogram (ECG). You should have these tests:
Children
Caprelsa should not be given to children below 5 years of age.
Other medicines and Caprelsa Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines that you buy without a prescription and herbal medicines. This is because Caprelsa can affect the way some medicines work and some medicines can have an effect on Caprelsa.
Tell your doctor or pharmacist if you are taking any of the following medicines:
You will also find this information in the Patient Alert Card you have been given by your doctor. It is important that you keep this Alert Card and show it to your partner or caregivers.
Pregnancy and breast-feeding
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine. This is because Caprelsa may harm an unborn child. Your doctor will discuss with you the benefits and risks of taking Caprelsa during this time.
Driving and using machines Use caution before driving or using machines. Keep in mind Caprelsa may make you feel tired, weak, or cause blurred vision.
Use in adults Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.
Use in children and adolescents The doctor will tell you how many tablets of Caprelsa to give to your child. The amount of Caprelsa given will depend on your child s body weight and height. The total daily dose in children must not exceed 300 mg. The treatment may either be given to your child as a once-daily dose, an every other day dosing or a repeating 7-day schedule as indicated in the dosing guide that has been given to you by your doctor. It is important that you keep this dosing guide and show it to your caregiver.
If you have trouble swallowing the tablet
If you have trouble swallowing the tablet, you can mix it with water as follows:
If you get side effects
If you get side effects always tell your doctor. Your doctor may tell you to take Caprelsa at a lower or increased dose (such as two 100 mg tablets or one 100 mg tablet). Your doctor may also prescribe other medicines to help control your side effects. The side effects of Caprelsa are listed in Section 4. If you take more Caprelsa than you should If you take more Caprelsa than you have been prescribed, talk to a doctor or go to a hospital straight away.
If you forget to take Caprelsa What to do if you forget to take a tablet depends on how long it is until your next dose.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them. If you get side effects, your doctor may tell you to take Caprelsa at a lower dose. Your doctor may also prescribe other medicines to help control your side effects.
Tell your doctor straight away if you notice any of the following side effects you may need urgent medical treatment:
Other side effects include: Very common (affects more than 1 in 10 people):
Common (affects less than 1 in 10 people)
Uncommon (affects less than 1 in 100 people)
Not known (frequency cannot be estimated from the available data)
The following side effects may be shown in tests that may be carried out by your doctor:
If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist straight away.
Reporting of side effects
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the blister and the carton after EXP. The expiry date refers to the last day of that month.
Do not store above 30 C.
Do not throw away medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
What Caprelsa contains
What Caprelsa looks like and contents of the pack Caprelsa 100 mg is a white round film-coated tablet with Z100 imprinted on one side. Caprelsa 300 mg is a white oval-shaped film-coated tablet with Z300 imprinted on one side.
Caprelsa comes in blister packs of 30 tablets.
Marketing Authorisation Holder Sanofi B.V.
Paasheuvelweg 1105 BP Amsterdam The Netherlands
Manufacturer Genzyme Ireland Ltd., IDA Industrial Park, Old Kilmeaden Road, Waterford, Ireland
Sanofi Winthrop Industrie, 30-36 avenue Gustave Eiffel, 37100 Tours, France
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
Belgi /Belgique/Belgien/ Luxembourg/Luxemburg Sanofi Belgium T l/Tel: + 32 (0)2 710 54 Magyarorsz g SANOFI-AVENTIS Zrt. Tel: +36 1 505 0
Swixx Biopharma EOOD
T : +359 (0)2 4942 Malta Sanofi S.r.l. Tel: +39 02 39394 esk republika sanofi-aventis, s.r.o. Tel: +420 233 086 Nederland Sanofi B.V. Tel: +31 20 245 4Danmark Sanofi A/S Tlf: +45 45 16 70 Norge sanofi-aventis Norge AS Tlf: + 47 67 10 71 Deutschland Sanofi-Aventis Deutschland GmbH Tel.: 0800 52 52 Tel. aus dem Ausland: +49 69 305 21 sterreich sanofi-aventis GmbH Tel: + 43 1 80 185 - 0
Eesti Swixx Biopharma O
Tel. +372 640 10 Polska sanofi-aventis Sp. z o.o. Tel.: +48 22 280 00
Sanofi-Aventis AEBE : +30 210 900 16 Portugal Sanofi Produtos Farmac uticos, Lda.
Tel: +351 21 35 89 Espa a sanofi-aventis, S.A. Tel: +34 93 485 94 Rom nia Sanofi Romania SRL Tel: +40 (0) 21 317 31 France Sanofi Winthrop Industrie T l: 0 800 222 Appel depuis l tranger: +33 1 57 63 23 Slovenija Swixx Biopharma d.o.o. Tel: +386 1 235 51 Hrvatska Swixx Biopharma d.o.o. Tel: +385 1 2078 Ireland sanofi-aventis Ireland Ltd. T/A SANOFI Tel: +353 (0) 1 403 56 Slovensk republika Swixx Biopharma s.r.o. Tel.: +421 2 208 33 sland Vistor hf. S mi: +354 535 7Suomi/Finland Sanofi Oy Puh/Tel: + 358 (0) 201 200 Italia Sanofi S.r.l. Tel: + 800 536
C.A. Papaellinas Ltd. : +357 22 741Sverige Sanofi AB Tel: +46 (0)8 634 50 Latvija Swixx Biopharma SIA Tel: +371 6 616 47 United Kingdom (Northern Ireland) sanofi-aventis Ireland Ltd. T/A SANOFI Tel: +44 (0) 800 035 2Lietuva Swixx Biopharma UAB Tel. +370 5 236 91 This leaflet was last revised in
Other sources of information
Detailed information on this medicine is available on the European Medicines Agency web site:
Entry 1 - fullUrl = Composition/composition-en-f3d8b9999dbf0bb7ed96cabee591db10
Resource Composition:
Generated Narrative: Composition composition-en-f3d8b9999dbf0bb7ed96cabee591db10
Language: en
Profile: Composition (ePI)
identifier:
http://ema.europa.eu/identifier
/EU/1/11/749/001status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - caprelsa
Attesters
Mode Time Official 2022-02-16 13:28:17+0000
Entry 2 - fullUrl = MedicinalProductDefinition/mpf3d8b9999dbf0bb7ed96cabee591db10
Resource MedicinalProductDefinition:
Generated Narrative: MedicinalProductDefinition mpf3d8b9999dbf0bb7ed96cabee591db10
identifier:
http://ema.europa.eu/identifier
/EU/1/11/749/001type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Caprelsa 100 mg film-coated tablets
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en